For 28 years, the Tissue Procurement Shared Resource (TPSR), rated in the last two CCSG reviews as """"""""outstanding"""""""", has been an important component of the research mission in the OSUCCC. The TPSR procures and provides malignant and normal tissues from solid tumors to the OSUCCC membership. The TPSR is part of a large tissue bank network at OSU entitled, """"""""The Human Tissue Resource Network"""""""" thal also includes: The NCI-funded Cooperative Human Tissue Network, the NCI-funded Cancer and Leukemia Group B (CALGB) Pathology Coordinating Office and specimen banks, the NCI-funded AIDS Malignancy Bank, the Tissue Archives Services and the Research Histology Core Facility. The strong institutional and coordinated support of groups compliments the TPSR to bring together the expertise and tools to direct tissue resource projects such as to enhance the support of the OSUCCC. The operation management and technical staff provide high quality and consistent tissue specimens that will likely prove critical to all six of the OSUCCC scientific programs. This service has been primarily a prospective tissue procurement service for basic science applications. However there is now a new effort to include pre-surgical (biopsy) and postsurgical collection of specimens for the purposes of clinical correlative studies by OSUCCC investigators. The TPSR efficiently accomplishes both basic science and clinical collection of materials that are fundamentally different yet both important to the goals of the OSUCCC. The TPSR staff provides quality control of the research specimen and direct interaction with pathologists and OSUCCC investigators to better assist in procurement of tissues and to foster hypothesis-driven cancer research. The TPSR has been used by five of the OSUCCC scientific programs with heavy use from the Molecular Biology and Cancer Genetics Program. All (100%) of the TPSR procurement usage is by OSUCCC members and 69.5% of the Laser Capture Microdissection activity has been by OSUCCC members, yet over the past four years only 65% of it's funding came from the CCSG. The TPSR seeks to continue to leverage strong institutional support of its services to provide for the expanding future needs for the OSUCCC. Indeed, in this application the CCSG support represents only 21.6% of the total TPSR cost. The collaboration between the hospitals, OSUCCC and the Department of Pathology to provide this service is demonstration of true synergy that adds ample value to the OSUCCC membership.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-34
Application #
7743466
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2010-11-30
Budget Start
2008-12-01
Budget End
2010-11-30
Support Year
34
Fiscal Year
2009
Total Cost
$264,603
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Pan, Pan; Huang, Yi-Wen; Oshima, Kiyoko et al. (2018) An immunological perspective for preventing cancer with berries. J Berry Res 8:163-175

Showing the most recent 10 out of 2602 publications